(Q38138412)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

BCG immunotherapy for bladder cancer--the effects of substrain differences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Christine Gan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hugh Mostafid

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Muhammad Shamim Khan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

17 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

580-588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2013.194

21 February 2020

exact match

0 references

cites work

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Influence of BCG vaccine strain on the immune response and protection against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Mapping the global use of different BCG vaccine strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

The BCG World Atlas: a database of global BCG vaccination policies and practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Genome plasticity of BCG and impact on vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Cellular response to mycobacteria: balancing protection and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Mutations in Mycobacterium tuberculosis Rv0444c, the gene encoding anti-SigK, explain high level expression of MPB70 and MPB83 in Mycobacterium bovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Revisiting the structure of the anti-neoplastic glucans of Mycobacterium bovis Bacille Calmette-Guerin. Structural analysis of the extracellular and boiling water extract-derived glucans of the vaccine substrains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Glycosaminoglycan content of human bladders. a method of analysis using cold-cup biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Intravesical BCG therapy in the management of multiple superficial bladder carcinoma. Comparison between Glaxo and Pasteur strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Immunotherapy of ovarian cancer with cell wall skeleton ofMycobacterium bovisBacillus Calmette-Guérin: Effect of lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Identification of substrains of BCG vaccine using multiplex PCR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Identification of two subpopulations of Bacillus Calmette-Guérin (BCG) Tokyo172 substrain with different RD16 regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guérin Substrains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

Tuberculosis vaccines: time to think about the next generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.194

[Treatment of patients with recurrent superficial bladder cancer with lyophilized Moureau-Rio de Janeiro BCG strain. Brazillian National Cancer Institute experience]

31 March 2020

1 reference

12 December 2020

A bibliography of the complications of BCG vaccination. A comprehensive list of the world literature since the introduction of BCG up to July 1982, supplemented by over 100 personal communications

1 reference

12 December 2020

BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics

1 reference

12 December 2020

Activation of natural killer cells by Bacillus Calmette-Guérin

1 reference

12 December 2020

Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East C

1 reference

12 December 2020

Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections.

1 reference

12 December 2020

Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria

1 reference

12 December 2020

The BCG story: lessons from the past and implications for the future

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

Studies on the biological activity of two strains of BCG: influence of production conditions.

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Treatment of patients with superficial bladder cancer stratified by risk groups treated with lyophilized Moreau-Rio de Janeiro BCG strain

1 reference

12 December 2020

Comparative studies with various substrains of Mycobacterium bovis BCG on the production of an antigenic protein, MPB70

1 reference

12 December 2020

Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety

1 reference

12 December 2020

Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 February 2020

1005612478

0 references

Fatcat ID

release_ee74xhxg45cgvcptnjovhnxda4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ee74xhxg45cgvcptnjovhnxda4

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24042563%20AND%20SRC:MED&resulttype=core&format=json